- Conditions
- Cancer, Malignancy, Neoplasia, Neoplasm, Neoplasm Metastasis, Colon Cancer, Colonic Neoplasms, Colon Cancer Liver Metastasis, Metastatic Cancer, Metastatic Melanoma, Metastatic Colon Cancer, Metastatic Lung Cancer, Non Small Cell Lung Cancer Metastatic, Pancreatic Cancer, Pancreas Cancer, Pancreas Adenocarcinoma, Pancreas Neoplasm, Metastatic Nonsmall Cell Lung Cancer, Metastatic Pancreatic Cancer
- Interventions
- ASN007: ascending doses, ASN007 RD
- Drug
- Lead sponsor
- Asana BioSciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Boston, Massachusetts • Houston, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,108
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
- Interventions
- ONC-392, Pembrolizumab, Docetaxel
- Drug
- Lead sponsor
- OncoC4, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 733 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 33
- States / cities
- Springdale, Arkansas • Davis, California • Downey, California + 27 more
- Conditions
- Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Interventions
- Pembrolizumab, Flt3L, Radiation, Poly ICLC
- Drug · Radiation
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Breast Fibrocystic Change, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Interventions
- Abemaciclib, Therapeutic Conventional Surgery
- Drug · Procedure
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Early-Stage Breast Carcinoma
- Interventions
- Cyrcadia CBR™ device placement for abnormality screening
- Device
- Lead sponsor
- Cyrcadia Health
- Industry
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 2
- States / cities
- Mountain View, California • Columbus, Ohio
- Conditions
- Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- laboratory biomarker analysis, questionnaire administration
- Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
- Conditions
- Breast Cancer, Cognitive Impairment
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 40 Years to 70 Years · Female only
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage 2 Breast Cancer AJCC v8, Anatomic Stage 3 Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, Invasive Breast Carcinoma, Triple Negative Breast Carcinoma
- Interventions
- Best Practice, Stereotactic Body Radiation Therapy, Resection, Sentinel Lymph Node Biopsy, Dietary Intervention, Questionnaire Administration, Quality-of-Life Assessment, Mammography, Biospecimen Collection
- Other · Radiation · Procedure
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Familial Pancreatic Cancer
- Interventions
- biologic sample preservation procedure, medical chart review, survey administration
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 1,122 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Renal Cell Carcinoma, Gastric Cancer, Metastatic Breast Cancer, Small-cell Lung Cancer, Other Solid Tumors
- Interventions
- HC-5404-FU
- Drug
- Lead sponsor
- HiberCell, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • Saint Paul, Minnesota • Dallas, Texas + 1 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Urothelial Carcinoma, Malignant Melanoma, Head and Neck Squamous Cell Carcinoma
- Interventions
- CAN04, Pembrolizumab, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Cantargia AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Lake Mary, Florida • Philadelphia, Pennsylvania
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers
- Interventions
- Autogene cevumeran, Atezolizumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Brain Neoplasms, Neoplasm Metastasis
- Interventions
- Stereotactic surgery (SRS), Craniotomy
- Procedure
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ewing Sarcoma, Gastrointestinal Tumor, Germ Cell Tumor, Hepatic Tumor, Lymphoma, Wilms Tumor, Rhabdoid Tumor, Clear Cell Carcinoma, Renal Cell Carcinoma, Melanoma, Neuroblastoma, Rhabdomyosarcoma, Non-rhabdomyosarcoma
- Interventions
- alemtuzumab, fludarabine, sirolimus, Busulfan, melphalan, stem cells, CliniMACS
- Drug · Biological · Device
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2020
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Cancer
- Interventions
- protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
- Genetic · Other · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- Up to 120 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Breast Carcinoma, Lymphedema
- Interventions
- Best Practice, Motivational Interviewing, Quality-of-Life Assessment, Questionnaire Administration
- Other · Behavioral
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC, Melanoma, Advanced Gastrointestinal Stromal Tumors (GIST), Advanced NRAS/BRAFT wt Cutaneous Melanoma
- Interventions
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 4
- States / cities
- Tampa, Florida • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Breast Carcinoma
- Interventions
- Best Practice, Discussion, Interview - Stakeholder, Interview - Key Informant, Interview - Ancillary studies, Patient Navigation - C Components, Patient Navigation - B components, Patient Navigation - A components, Survey Administration, Survey Administration - Ancillary studies
- Other · Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer
- Interventions
- Internet-Based Intervention, Survey Administration
- Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Charlestown, Massachusetts • New Brunswick, New Jersey • New York, New York
- Conditions
- Basal Cell Carcinoma, Squamous Cell Carcinoma of the Skin
- Interventions
- CivaDerm
- Device
- Lead sponsor
- CivaTech Oncology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Morrisville, North Carolina
- Conditions
- Breast Neoplasms, Breast Diseases, Breast Fibroadenoma, Breast Cancer
- Interventions
- Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non-Melanoma Skin Cancers
- Interventions
- SM-020 1% Gel
- Drug
- Lead sponsor
- DermBiont, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Melanoma, Uveal Melanoma, Merkel Cell Carcinoma, Mesothelioma, MSI, Non-small Cell Lung Cancer, NSCLC, Ovarian Cancer, Squamous Cell Carcinoma of the Head and Neck, Small Cell Lung Cancer, Renal Cell Carcinoma, RCC, Triple-negative Breast Cancer, Urothelial Carcinoma, Mismatch Repair Deficiency
- Interventions
- INCAGN02390
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Jackson, Mississippi • Hackensack, New Jersey + 1 more
- Conditions
- HER2-positive Breast Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
- Interventions
- pNGVL3-hICD vaccine, sargramostim, flow cytometry, immunologic technique, immunoenzyme technique, protein expression analysis, biopsy
- Biological · Other · Genetic + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington